Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib and Gemcitabine in Pediatric Solid Tumors
NCT05093322Phase 2Completed
- Sponsor
- HUTCHMED
- Start
- Nov 2021
- Primary completion
- Apr 2023
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in osteosarcoma (OS), Ewing sarcoma, rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), sponsored by HUTCHMED. Started Nov 2021; status: completed.
02
Drugs
surufatinib
03
Conditions
osteosarcoma (OS)Ewing sarcomarhabdomyosarcoma (RMS)non-rhabdomyosarcoma soft tissue sarcoma (NRSTS)
Beyond the preview
Go deeper on NCT05093322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05093322.